Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Disc Medicine Inc IRON

Healthcare Biotechnology
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond... see more

Current News (NDAQ:IRON)

Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire 10 days ago

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire 13 days ago

Disc Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire October 31, 2025

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire October 21, 2025

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire October 20, 2025

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

GlobeNewswire October 20, 2025

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

GlobeNewswire October 17, 2025

Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)

GlobeNewswire October 16, 2025

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

GlobeNewswire September 30, 2025
View More News ››

Opinion & Analysis (NDAQ:IRON)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IRON)

Be the first to post on this bullboard.

Mullen Group Ltd.

Mullen Group Ltd.

Mullen Group is one of North America's largest logistics providers with a network of independently operated businesses ...
View More »